Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

The Effects of ARBs, ACEis, and Statins on Clinical Outcomes of COVID-19 Infection Among Nursing Home Residents
Anton De Spiegeleer, Antoon Bronselaer, James Teo, et al.
Journal of the American Medical Directors Association (2020) Vol. 21, Iss. 7, pp. 909-914.e2
Open Access | Times Cited: 168

Showing 26-50 of 168 citing articles:

Protective Effects of Statins Administration in European and North American Patients Infected with COVID-19: A Meta-Analysis
Mairi Pucci, Diletta Onorato, Giovanni Carpenè, et al.
Seminars in Thrombosis and Hemostasis (2021) Vol. 47, Iss. 04, pp. 392-399
Open Access | Times Cited: 49
Relation of prior statin and anti-hypertensive use to severity of disease among patients hospitalized with COVID-19: Findings from the American Heart Association’s COVID-19 Cardiovascular Disease Registry
Lori B. Daniels, Junting Ren, Kris Kumar, et al.
PLoS ONE (2021) Vol. 16, Iss. 7, pp. e0254635-e0254635
Open Access | Times Cited: 44
Statins use and COVID-19 outcomes in hospitalized patients
Samuel K. Ayeh, Enoch J. Abbey, Banda A. A. Khalifa, et al.
PLoS ONE (2021) Vol. 16, Iss. 9, pp. e0256899-e0256899
Open Access | Times Cited: 43
The use of statins was associated with reduced COVID-19 mortality: a systematic review and meta-analysis
Kuan‐Sheng Wu, Pei‐Chin Lin, Yao-Shen Chen, et al.
Annals of Medicine (2021) Vol. 53, Iss. 1, pp. 874-884
Open Access | Times Cited: 42
Renin–angiotensin-system inhibitors and all-cause mortality in patients with COVID-19: a systematic review and meta-analysis of observational studies
Chirag Bavishi, Paul K. Whelton, Giuseppe Mancia, et al.
Journal of Hypertension (2021) Vol. 39, Iss. 4, pp. 784-794
Open Access | Times Cited: 41
Protective effects of statins on COVID-19 risk, severity and fatal outcome: a nationwide Swedish cohort study
Ailiana Santosa, Stefan Franzén, Jonatan Nåtman, et al.
Scientific Reports (2022) Vol. 12, Iss. 1
Open Access | Times Cited: 33
Vascular endotheliitis associated with infections: Its pathogenetic role and therapeutic implication
Yuichi Hattori, Kohshi Hattori, Takuji Machida, et al.
Biochemical Pharmacology (2022) Vol. 197, pp. 114909-114909
Open Access | Times Cited: 32
Mortality and Severity in COVID-19 Patients on ACEIs and ARBs—A Systematic Review, Meta-Analysis, and Meta-Regression Analysis
Romil Singh, Sawai Singh Rathore, Hira Khan, et al.
Frontiers in Medicine (2022) Vol. 8
Open Access | Times Cited: 28
Survival of the hospitalized patients with COVID‐19 receiving atorvastatin: A randomized clinical trial
Majid Ghafoori, Hassan Saadati, Mohammadreza Taghavi, et al.
Journal of Medical Virology (2022) Vol. 94, Iss. 7, pp. 3160-3168
Open Access | Times Cited: 27
Recent advances in nutritional metabolism studies on SARS-CoV-2 infection
Yue Jiang, Xu Li, Xuexing Zheng, et al.
Infectious Medicine (2025) Vol. 4, Iss. 1, pp. 100162-100162
Open Access
Lipid-targeting antiviral strategies: current state and future perspectives
Ana-Belén Blázquez, Patricia Mingo‐Casas, Ernesto Quesada, et al.
Antiviral Research (2025), pp. 106103-106103
Closed Access
Renin-Angiotensin System Inhibitors and COVID-19: a Systematic Review and Meta-Analysis. Evidence for Significant Geographical Disparities
Dimitrios Patoulias, Alexandra Katsimardou, Konstantinos Stavropoulos, et al.
Current Hypertension Reports (2020) Vol. 22, Iss. 11
Open Access | Times Cited: 46
Pharmacotherapy in COVID-19 patients: a review of ACE2-raising drugs and their clinical safety
Saghir Akhtar, Ibrahim F. Benter, Mohammed Danjuma, et al.
Journal of drug targeting (2020) Vol. 28, Iss. 7-8, pp. 683-699
Open Access | Times Cited: 44
The Effect of Prior Angiotensin-Converting Enzyme Inhibitor and Angiotensin Receptor Blocker Treatment on Coronavirus Disease 2019 (COVID-19) Susceptibility and Outcome: A Systematic Review and Meta-analysis
Jiuyang Xu, Yaqun Teng, Lianhan Shang, et al.
Clinical Infectious Diseases (2020) Vol. 72, Iss. 11, pp. e901-e913
Open Access | Times Cited: 41
A comprehensive guide to the pharmacologic regulation of angiotensin converting enzyme 2 (ACE2), the SARS-CoV-2 entry receptor
Murat Öz, Dietrich E. Lorke, Nadine Kabbani
Pharmacology & Therapeutics (2020) Vol. 221, pp. 107750-107750
Open Access | Times Cited: 41
Statin and outcomes of coronavirus disease 2019 (COVID-19): A systematic review, meta-analysis, and meta-regression
Timotius Ivan Hariyanto, Andree Kurniawan
Nutrition Metabolism and Cardiovascular Diseases (2021) Vol. 31, Iss. 6, pp. 1662-1670
Open Access | Times Cited: 39
The protective association between statins use and adverse outcomes among COVID-19 patients: A systematic review and meta-analysis
Ronald Chow, James Im, Nicholas Chiu, et al.
PLoS ONE (2021) Vol. 16, Iss. 6, pp. e0253576-e0253576
Open Access | Times Cited: 37
HMG-CoA reductase inhibitors and COVID-19 mortality in Stockholm, Sweden: A registry-based cohort study
Rita Bergqvist, Viktor H. Ahlqvist, Michael Lundberg, et al.
PLoS Medicine (2021) Vol. 18, Iss. 10, pp. e1003820-e1003820
Open Access | Times Cited: 34
The Association Between the Use of Statins and Clinical Outcomes in Patients with COVID-19: A Systematic Review and Meta-analysis
Chia Siang Kow, Syed Shahzad Hasan
American Journal of Cardiovascular Drugs (2021) Vol. 22, Iss. 2, pp. 167-181
Open Access | Times Cited: 32
Correlation of SARS‑CoV‑2 to cancer: Carcinogenic or anticancer? (Review)
Yingshuang Li, Hua-Cheng Ren, Jianhua Cao
International Journal of Oncology (2022) Vol. 60, Iss. 4
Open Access | Times Cited: 23
Cholesterol-modifying drugs in COVID-19
Nathalie Schmidt, Peter A. C. Wing, Jane A. McKeating, et al.
Oxford Open Immunology (2020) Vol. 1, Iss. 1
Open Access | Times Cited: 36
Comparison of infection risks and clinical outcomes in patients with and without SARS‐CoV‐2 lung infection under renin–angiotensin–aldosterone system blockade: Systematic review and meta‐analysis
Chang Chu, Shufei Zeng, Ahmed A. Hasan, et al.
British Journal of Clinical Pharmacology (2020) Vol. 87, Iss. 6, pp. 2475-2492
Open Access | Times Cited: 36
COVID-19 In-Hospital Mortality and Use of Renin-Angiotensin System Blockers in Geriatrics Patients
Bastien Genet, Jean‐Sébastien Vidal, Adrien Cohen, et al.
Journal of the American Medical Directors Association (2020) Vol. 21, Iss. 11, pp. 1539-1545
Open Access | Times Cited: 35
Statins and SARS-CoV-2 disease: Current concepts and possible benefits
Madhu Mary Minz, Manish Bansal, Ravi R. Kasliwal
Diabetes & Metabolic Syndrome Clinical Research & Reviews (2020) Vol. 14, Iss. 6, pp. 2063-2067
Open Access | Times Cited: 34
Association of Statin Use With the In-Hospital Outcomes of 2019-Coronavirus Disease Patients: A Retrospective Study
Yongzhen Fan, Tao Guo, Feifei Yan, et al.
Frontiers in Medicine (2020) Vol. 7
Open Access | Times Cited: 33

Scroll to top